{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:22:52Z","timestamp":1789014172172,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.yrtph.2026.106066","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T07:43:18Z","timestamp":1771918998000},"page":"106066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Opportunities for reducing animal use in the development of intravitreal biotherapeutics"],"prefix":"10.1016","volume":"168","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5188-9960","authenticated-orcid":false,"given":"Helen","family":"Booler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Desnoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Freichel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Bantseev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.yrtph.2026.106066_bib1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1177\/0192623320971571","article-title":"Intravitreal administration of acetyl triethyl citrate and benzyl benzoate is retinotoxic in rabbits but not in cynomolgus monkeys","volume":"49","author":"Andaya","year":"2021","journal-title":"Toxicol. Pathol."},{"issue":"1\u20132","key":"10.1016\/j.yrtph.2026.106066_bib2","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1089\/jop.2017.0063","article-title":"Nonclinical safety assessment of anti-factor D: key strategies and challenges for the nonclinical development of intravitreal biologics","volume":"34","author":"Bantseev","year":"2018","journal-title":"J. Ocul. Pharmacol. Therapeut. : Off. J. Assoc. Ocular Pharmacol. Therap."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106066_bib3","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1167\/iovs.16-21356","article-title":"Determination of a no-observable effect level for endotoxin following a single intravitreal administration to dutch belted rabbits","volume":"58","author":"Bantseev","year":"2017","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106066_bib4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1089\/jop.2018.0149","article-title":"Determination of a no observable effect level for endotoxin following a single intravitreal administration to cynomolgus monkeys","volume":"35","author":"Bantseev","year":"2019","journal-title":"J. Ocul. Pharmacol. Therapeut."},{"key":"10.1016\/j.yrtph.2026.106066_bib5","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.yrtph.2016.08.012","article-title":"Non-clinical safety evaluation of biotherapeutics \u2013 challenges, opportunities and new insights","volume":"80","author":"Blaich","year":"2016","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106066_bib6","series-title":"Haschek and Rousseaux's Handbook of Toxicologic Pathology, Volume 4: Toxicologic Pathology of Organ Systems","article-title":"The eye","author":"Booler","year":"2024"},{"issue":"2","key":"10.1016\/j.yrtph.2026.106066_bib7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/01926233211047562","article-title":"Scientific and regulatory policy committee points to consider: fixation, trimming, and sectioning of nonrodent eyes and ocular tissues for examination in ocular and general toxicity studies","volume":"50","author":"Booler","year":"2022","journal-title":"Toxicol. Pathol."},{"issue":"12","key":"10.1016\/j.yrtph.2026.106066_bib8","doi-asserted-by":"crossref","DOI":"10.1167\/tvst.13.12.32","article-title":"Phase 1b dose escalation study of sozinibercept inhibition of vascular endothelial growth factors C and D with aflibercept for diabetic macular edema","volume":"13","author":"Boyer","year":"2024","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.yrtph.2026.106066_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2022.105329","article-title":"Re-evaluating the need for chronic toxicity studies with therapeutic monoclonal antibodies, using a weight of evidence approach","volume":"138","author":"Chien","year":"2023","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106066_bib10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.yrtph.2007.08.001","article-title":"Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: is 6 months still appropriate?","volume":"50","author":"Clarke","year":"2008","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.yrtph.2026.106066_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.yrtph.2017.03.013","article-title":"Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics","volume":"86","author":"de Zafra","year":"2017","journal-title":"Regul. Toxicol. Pharmacol."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106066_bib12","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1177\/0192623320976095","article-title":"Nonclinical safety assessment of FHTR2163, an antigen-binding fragment against HTRA1 for the treatment of geographic atrophy","volume":"49","author":"Dere","year":"2021","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2026.106066_bib13","series-title":"Reflection Paper on Non-human Primates in Safety Testing of Human Medicinal Products and Opportunities for 3Rs Implementation","year":"2025"},{"issue":"6","key":"10.1016\/j.yrtph.2026.106066_bib15","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaophthalmol.2018.1544","article-title":"Efficacy and safety of lampalizumab for geographic atrophy due to age-related macular degeneration: chroma and spectri phase 3 randomized clinical trials","volume":"136","author":"Holz","year":"2018","journal-title":"JAMA Ophthalmol."},{"key":"10.1016\/j.yrtph.2026.106066_bib17","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ajo.2021.06.017","article-title":"Phase 1 study of the Anti-HtrA1 antibody-binding fragment FHTR2163 in geographic atrophy secondary to age-related macular degeneration","volume":"232","author":"Khanani","year":"2021","journal-title":"Am. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106066_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2021035222","article-title":"Role of in vitro models for development of ophthalmic delivery systems","volume":"38","author":"Kutlehria","year":"2021","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"issue":"1","key":"10.1016\/j.yrtph.2026.106066_bib19","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/0192623313510987","article-title":"Immunogenicity\/hypersensitivity of biologics","volume":"42","author":"Leach","year":"2014","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2026.106066_bib20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-3-540-73259-4_2","article-title":"Preclinical safety evaluation of monoclonal antibodies","volume":"181","author":"Lynch","year":"2008","journal-title":"Handb. Exp. Pharmacol."},{"issue":"5","key":"10.1016\/j.yrtph.2026.106066_bib21","article-title":"HORNBILL: a first-in-human phase I\/IIa study of the safety, tolerability, and early pharmacodynamics of BI 764524 for diabetic macular ischemia","volume":"5","author":"Nguyen","year":"2025","journal-title":"Ophthalmol. Sci."},{"issue":"2","key":"10.1016\/j.yrtph.2026.106066_bib22","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0300985811415701","article-title":"Appropriate use of recovery groups in nonclinical toxicity studies: value in a science-driven case-by-case approach","volume":"49","author":"Pandher","year":"2012","journal-title":"Veterinary Pathol."},{"issue":"8","key":"10.1016\/j.yrtph.2026.106066_bib23","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/0192623313481513","article-title":"Society of toxicologic pathology position paper on best practices on recovery studies:the role of the anatomic pathologist","volume":"41","author":"Perry","year":"2013","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.yrtph.2026.106066_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105339","article-title":"The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remain","volume":"138","author":"Prior","year":"2023","journal-title":"Regul. Toxicol. Pharmacol. : RTP (Regul. Toxicol. Pharmacol.)"},{"issue":"5","key":"10.1016\/j.yrtph.2026.106066_bib25","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/cts.13480","article-title":"International consortium for innovation and quality: an industry perspective on the nonclinical and early clinical development of intravitreal drugs","volume":"16","author":"Pruimboom-Brees","year":"2023","journal-title":"Clin. Transl. Sci."},{"issue":"3","key":"10.1016\/j.yrtph.2026.106066_bib26","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1177\/0192623320978396","article-title":"Immunology and pathology in ocular drug development","volume":"49","author":"Ramos","year":"2021","journal-title":"Toxicol. Pathol."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106066_bib27","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1177\/0192623314526475","article-title":"Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes","volume":"42","author":"Rojko","year":"2014","journal-title":"Toxicol. Pathol."},{"issue":"4","key":"10.1016\/j.yrtph.2026.106066_bib28","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1177\/10915818241243350","article-title":"Recovery animals in toxicology studies: an innovation and quality consortium perspective on best practices with case study examples","volume":"43","author":"Salian-Mehta","year":"2024","journal-title":"Int. J. Toxicol."},{"issue":"13","key":"10.1016\/j.yrtph.2026.106066_bib29","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1167\/iovs.18-26349","article-title":"Rapid development of glaucoma via ITV nonselective ANGPT 1\/2 antibody: a potential role for ANGPT\/TIE2 signaling in primate aqueous humor outflow","volume":"60","author":"Thackaberry","year":"2019","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.yrtph.2026.106066_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.00545","article-title":"HTRA1-Related cerebral small vessel disease: a review of the literature","volume":"11","author":"Uemura","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.yrtph.2026.106066_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2021.104953","article-title":"Implementation of the principles of the 3Rs of animal testing at CDER: past, present and future","volume":"123","author":"Wange","year":"2021","journal-title":"Regul. Toxicol. Pharmacol."}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026000395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230026000395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:14:49Z","timestamp":1775906089000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230026000395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":29,"alternative-id":["S0273230026000395"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106066","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Opportunities for reducing animal use in the development of intravitreal biotherapeutics","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2026.106066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106066"}}